NEW YORK, July 22, 2015 /PRNewswire/ --

ACI Association has initiated research coverage on Receptos, Inc. (NASDAQ: RCPT). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.

Today, membership is open to readers on a complementary basis at the following URL: http://www.aciassociation.com/?c=RCPT

Highlights from our RCPT Report include: 


        
        - Positive Results for the Maintenance period of Clinical Trial - On April 16, 2015,
          Receptos, Inc. reported positive results for the maintenance period of TOUCHSTONE, the
          Phase 2 trial of ozanimod (formerly RPC1063) in ulcerative colitis (UC). The results
          showed that the study has met all efficacy endpoints with statistical significance in
          patients on the 1 mg dose of ozanimod after 32 weeks of treatment.



        
        - Assessment Of Ozanimod Versus Placebo In Details - The aforesaid study evaluated
          the efficacy, safety and tolerability of two orally administered doses (0.5 mg and 1
          mg) of ozanimod versus placebo. This randomized, double-blind, placebo-controlled
          trial was conducted in 199 patients with moderately-to-severely active UC across 57
          sites in 13 countries. Receptos informed that the trial met its primary efficacy and
          all secondary endpoints for patients with 1 mg dose after 8 weeks of treatment in the
          induction period. The 103 patients, who achieved clinical response in the maintenance
          period at the eight week, continued with treatment for 24 more weeks. At week 32, all
          secondary end-points were positive and statistically significant for the 1 mg dose.
          The secondary endpoints at week 32 included clinical response, change in the industry
          standard Mayo score and mucosal improvement on endoscopy. Further, the proportion of
          patients in clinical remission at week 32 was statistically significant in favor of
          both the 1 mg group and the 0.5 mg group (p < 0.05) compared to placebo.



        
        - Plans to start Phase 3 Trial - In 2015, the Company plans to go ahead with a Phase
          3 program to confirm the findings of Phase 2. The phase 3 trial would be conducted in
          patients with moderately-to-severely active UC. Furthermore, these results continue to
          suggest the potential for ozanimod to be used in the treatment of a related
          inflammatory bowel disease called Crohn's.  The Company stated that it would be
          initiating a Phase 2 study of ozanimod for the treatment of Crohn's disease in 2015.



        
        - Management's Comments - President and Chief Executive Officer of Receptos, Faheem
          Hasnain said, "The positive results of the maintenance period of the TOUCHSTONE study
          exceeded our expectations with respect to the potential for long term clinical benefit
          of ozanimod in ulcerative colitis." He added, "The consistency of the efficacy data
          across the various endpoints for the high dose, combined with the favorable safety
          profile, gives us continued confidence to advance the development of ozanimod in
          inflammatory bowel disease."

To find out how this influences our rating on Receptos, Inc. read the full report in its entirety here: http://www.aciassociation.com/?c=RCPT

About ACI Association: 

Active Charter Investors Association ("ACI Association") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ACI Association has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ACI Association has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:  

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA(R) charter holder (the "CFA(R)"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA(R) have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA(R) (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.

NO WARRANTY 

ACI Association, the Author, the Reviewer and the CFA(R) (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ACI Association nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.aciassociation.com.

RESTRICTIONS 

ACI Association is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at) aciassociation.com.

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE www.aciassociation.com